Maybank

Raffles Medical Group (RFMD SP)

Seeking new growth drivers

Acquires Ho Chi Minh City hospital; maintain BUY

RFMD is acquiring a majority interest in American International Hospital (AIH, not listed) in Ho Chi Minh City for up to USD45.6m, to be fully funded by internal resources. The consideration took into account the valuation of the hospital asset by Savills Vietnam in Jul 2023. This follows a strategic partnership agreement it entered with My My Trading Services Company (not listed). Meanwhile, RFMD extended its contract to provide medical services at Connect@Changi as a TCF/CTF until Feb 2025. Maintain BUY and a DCF-based TP of SGD1.65 (LTG: 3%, COE: 8%).

Expands to fast-growing Vietnamese market

Located in An Phu Ward, Thu Duc City, Ho Chi Minh, AlH is a purpose-built and fully equipped 120-bed tertiary hospital. AlH has five operating theatres and offers a full range of specialist and essential diagnostic capabilities. AlH is a JCI-accredited hospital and has been managed by its founders after opening in 2018. Management says AlH has seen steady growth in both outpatient and inpatient volumes since inception. That said, we do not expect any near-term contribution from this proposed acquisition, which may take at least 6-9 months to complete, subject to the fulfilment of certain conditions and relevant approvals.

Part of long-term strategy to diversify revenues

As part of the deal, RFMD will enter into a management service agreement to manage AIH's operations. It currently has about 500 staff, including 60 doctors. This will enable RMG to ride on growing demand for private healthcare services in Vietnam and augment its clinic operations there. Leveraging on its strong balance sheet, we believe this is an integral part of RFMD's long-term strategy to expand its income stream, while diversifying the group's hospital operations beyond Singapore and China.

Secures extension contract for TCF at Changi

RFMD recently secured a contract to continue providing medical services at Connect@Changi as a TCF/CTF until Feb 2025. According to GeBiz, there was a total of nine bidders for the open tender. While its winning bid value of SGD151,392 per month was c.54% lower than the next closest bidder, this is enabled by significant savings for one-off set-up costs for the TCF/CTF as the group is already an existing operator. Nevertheless, we expect margins to normalise given the higher opex of running the facility.

FYE Dec (SGD m)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	724	767	740	749	763
EBITDA	161	236	206	213	223
Core net profit	84	144	120	126	132
Core EPS (cts)	4.5	7.6	6.4	6.7	7.0
Core EPS growth (%)	24.0	69.6	(16.2)	4.6	5.0
Net DPS (cts)	2.8	3.8	3.2	3.3	3.5
Core P/E (x)	30.4	18.3	19.2	18.4	17.5
P/BV (x)	2.7	2.6	2.1	2.0	1.9
Net dividend yield (%)	2.0	2.7	2.6	2.7	2.9
ROAE (%)	9.1	14.5	11.5	11.4	11.3
ROAA (%)	5.7	9.4	7.8	7.8	7.9
EV/EBITDA (x)	15.5	10.4	10.4	9.7	8.9
Net gearing (%) (incl perps)	net cash				
Consensus net profit	-	-	121	124	127
MIBG vs. Consensus (%)	-	-	(0.7)	1.4	3.7

Eric Ong ericong@maybank.com (65) 6231 5849

BUY

Share Price SGD 1.23
12m Price Target SGD 1.65 (+34%)
Previous Price Target SGD 1.65

Company Description

Raffles Medical owns and operates hospitals and medical clinics in the region


Statistics

52w high/low (SGD)	1.50/1.21
3m avg turnover (USDm)	1.2
Free float (%)	43.8
Issued shares (m)	1,880
Market capitalisation	SGD2.3B
	USD1.7B

Major shareholders:

LOO CHOON YONG	49.9%
S&D Holdings Pte Ltd.	3.3%
Global Alpha Capital Management Ltd.	1.9%

Price Performance



Raffles Medical - (LHS, SGD) Raffles Medical / Straits Times Index - (RHS, %)

	- 1741	-3M	- I Z/M
Absolute (%)	(2)	(11)	(7)
Relative to index (%)	(0)	(11)	(8)

Source: FactSet

Abbreviations:

JCI: Joint Commission International TCF: Transitional Care Facilities CTF: Covid-19 treatment facility




Maybank

Value Proposition

- Provides private medical services that fill the gap between cheap-but-slow public services and fast-and-affordable private healthcare.
- Foreign patient volumes and elective procedures could recover in line with easing borders restrictions.
- As the market in Singapore becomes saturated, we expect China to be the next long-term growth engine.


Strong regional presence



Source: Company

Price Drivers

Historical share price trend



Source: Company, FactSet, Maybank IBG Research


- 1. Signed an MOU with China Taiping to jointly provide medical / healthcare insurance solutions.
- 2. Opened Raffles Hospital Chongqing a 700 bed hospital with GFA of more than 100,000 sqm.
- 3. Signed MOU with China Life Insurance to provide medical services, and healthcare management/financing.
- 4. Raffles Hospital Shanghai a 400 bed tertiary hospital spanning 70,000 sqm officially opened in Pudong Qiatan.

Financial Metrics

- While FY23E EPS may decline due to lower Covid-19-related services, we believe improving local and foreign patient volumes should help to offset some of the adverse impact.
- Balance sheet is strong with net cash position, which enables the group to maintain its core payout ratio of c.50%.
- Capex should gradually revert to normalised levels with the completion of its Raffles Hospital Shanghai.

Net profit, margin and revenue

Source: Company, Maybank IBG Research



Swing Factors

Upside

- Faster-than-expected breakeven of new China hospitals.
- Cyclical recovery of foreign patient volumes.
- Stronger-than-expected EPS growth from higher revenue intensity, market share gains, etc.

Downside

- Further delay in EBITDA breakeven for Chongqing and Shanghai hospitals due to slowdown in China's recovery.
- Loss of competiveness of medical tourism in Singapore.
- Decline in domestic market share due to increased competitive pressures from both private and public hospitals.

ericong@maybank.com

Raffles Medical Group





ericong@maybank.com

Risk Rating & Score ¹	25.5
Score Momentum ²	-1.5
Last Updated	14 April 2023
Controversy Score ³ (Updated: 05 July 2017)	Low -1

Business Model & Industry Issues

- As a medical services provider, regulatory compliance and patient safety are among the highest priorities for both RMG and stakeholders. Employees' welfare, access to healthcare, economic performance and customer experience are also important priorities. The lowest priorities include waste and local supplies.
- While RMG sees energy and water usage as of medium significance, whereas stakeholders view these as low priority.
- RMG complies with all relevant laws and regulations and it submits periodic reports to relevant parties. RMG also has procedures to safeguard customer information.
- Raffles Hospital Singapore has been JCI accredited since 2008, and it has various committees to review clinical quality to promote patient safety.

Material E issues

- Raffles Hospital Singapore received the Green Mark certification in 2019 by the Building & Construction Authority. Among other requirements, Green Mark buildings have to maintain temperature in public areas within 24-26C and relative humidity less than 65%.
- In 2022, the water consumption index improved to 1.01m3/GFA (2021: 1.03); the electricity consumption index slightly increased to 0.18 MWh/GFA) from 0.16; and paper recycling tonnage improved to 83 tons from 48 tons.
- Among practical measures that RMG has taken to be more energy and water efficient are to install smart meters, timers and motion sensors, as well as water-efficient fittings.

Material S issues

- RMG trains physicians, nurses, allied health and healthcare managers in collaboration with local medical schools, polytechnics and vocational institutions to provide clinical training for undergraduates and postgraduates.
- It observes fair employment practices and also promotes workplace diversity as this is an advantage in catering to its various patient groups.
- As at 2022, RMG had a workforce of 2,678 permanent employees (FY21: 2,763).
- Average training hours per employee jumped to 19.3 in 2022 from 11.7 in 2021.
- Customer Satisfaction Index for its Raffles Hospital and Raffles Medical clinics remains relatively stable at 82% and 66% respectively.
- However, staff turnover rate rose to 36% in 2022 from 32% in 2021 due to the tight labour market.

Key G metrics and issues

- The board consists of 10 members, of which three are executives, including the founder, chairman and CEO Dr Loo Choon Yong, and one is non-executive and nonindependent. The remaining directors are independent (60%).
- The nominating, audit and remuneration committees are chaired by independent directors.
- Two independent directors have served for more than nine years. The board determined that these two directors remain independent.
- Auditor is KPMG LLP, appointed in 2019.
- RMG complies with all relevant statutory and regulatory requirements, and submits periodic reports to relevant government agencies and bodies.
- Raffles Hospital Singapore has been accredited by the JCI since 2008; a testament to its commitment to patient safety and care.
- There are several committees (e.g. medical audit committee, critical care committee etc) that look into the different areas of clinical quality. In addition, the quality committee has oversight of these committees with the aim to improve patient safety.
- RMG has clear policies relating to Personal Data Protection Act, and it has data protection officers to ensure adequate action is taken to protect personal data, including customers'. There was no incident of leak, theft or loss of customer data in 2022.

Rating & Score - derived by Sustainalytics and assesses the company's exposure to unmanaged ESG risks. Scores range between 0 - 50 in order of increasing severity with low/high scores & ratings representing negligible/significant risk to the company's enterprise value, respectively, from ESG-driven financial impacts. **2Score** Momentum** - indicates changes to the company's score since the last update - a negative integer indicates a company's improving risk score; a positive integer indicates a deterioration. **3Controversy Score** - reported periodically by Sustainalytics in the event of material ESG-related incident(s), with the impact severity scores of these events ranging from Category 0-5 (0 - no reports; 1 - negligible risks; ...; 5 - poses serious risks & indicative of potential structural deficiencies at the company).



	Quantitative Parameters (Score: 32)										
	Particulars	Unit	2020	2021	2022	KPJ MK (2022)					
	Scope 1 GHG emissions	m tCO2e	N/A	N/A	N/A	N/A					
	Scope 2 GHG emissions	m tCO2e	N/A	N/A	N/A	110.4					
	Total	m tCO2e	N/A	N/A	N/A	110.4					
	Scope 3 GHG emissions	m tCO2e	N/A	N/A	N/A	6.8					
	Total	m tCO2e	N/A	N/A	N/A	117.2					
	GHG intensity (Scope 1 and 2)	tCO2e/t	N/A	N/A	N/A	16.2					
Ε	Electricity consumption	MWh/GFA	0.19	0.16	0.18	0.16					
	Water consumption	m3/GFA	1.18	1.03	1.01	1.26					
	General waste (non-hazardous) consumption	ton/GFA	0.009	0.005	0.003	1.56					
	Biohazard Waste Index	ton/GFA	0.024	0.020	0.014	0.53					
	Paper recycled	tonnes	78	48	83	N/A					
	Food waste digested	tonnes	N/A	30	48	N/A					
	Cases of environmental non-compliance	number	0	0	0	0					
	% of women in workforce	%	N/A	N/A	N/A	78%					
S	% of women in senior management	%	27%	27%	27%	36%					
3	Average training hours per employee	hours	6.5	11.7	19.3	34					
	Employee volunteerism	hours	36	544	7176	352					
	CEO/MD salary as % of reported net profit	%	N/A	N/A	N/A	2.6%					
G	Board salary as % of reported net profit	%	3.0%	2.4%	1.7%	4.0%					
G	Independent directors on the Board	%	64%	64%	60%	45%					
	Female directors on the Board	%	18%	18%	20%	18%					

Qualitative Parameters (Score: 64)

a) is there an ESG policy in place and whether there is a standalone ESG committee or is it part of a risk committee?

Yes. The Committee is responsible for monitoring and overseeing the group's sustainability efforts and strategy.

b) Is the senior management salary linked to fulfilling ESG targets?

No

- c) Does the company follow the task force of climate related disclosures (TCFD) framework for ESG reporting?
- e) Does the company have a mechanism to capture Scope 3 emissions which parameters are captured? *No*
- f) What are the 2-3 key carbon mitigation/water/waste management strategies adopted by the company?

The group is embarking on projects that have significant savings in its cooling towers, such as adopting technology and reducing usage of chemical treatment in cooling tower maintenance. These will help achieve higher efficiency while reducing water consumption.

g) Does carbon offset form part of the net zero/carbon neutrality target of the company?

Yes

Target (Score: 80)		
Particulars	Target	Achieved
Reduce electricity consumption	10%	33%
Reduce general waste consumption	5%	44%
Reduce water consumption	5%	33%
Reduce food waste digested (tonnes)	30	30
Amount of paper recycled (tonnes)	50	48

Impact NA

Overall Score: 52

As per our ESG matrix, Raffles Medical Group (RFMD SP) has an overall score of 52.

ESG score	Weights	Scores	Final Score
Quantitative	50%	32	16
Qualitative	25%	64	16
Target	25%	80	20
Total			52

As per our ESG assessment, RFMD has an established framework, internal policies, and tangible mid/long-term targets but needs to make headway in improving its quantitative "E" metrics YoY. The group's overall ESG score is 52, which makes its ESG rating slightly above average, in our view (average ESG rating = 50; refer to our ESG Assessment Scoring).

Fig 1: Peer comparisons

											/EBITDA		
Company	BBG	MIBG	MKE TP	Price	FYE	Мсар		P/E	(x)		(x)	Div yield (%)	ROE (%)
	Code	Rec	(LC)	(LC)	mm/dd	USDm	Act	FY1	FY2	FY3	FY1	FY1	FY1
Raffles Med	RMFD SP	Buy	1.65	1.26	12	1,729	34.7	28.0	16.5	19.7	14.0	2.2	9.1
Singapore listed peers													
Q&M Dental	QNM SP	Hold	0.31	0.27	12	186	15.3	13.3	10.6	8.8	10.1	3.8	17.0
IHH Healthcare	IHH MK	-	-	5.81	12	10,833	35.2	30.6	27.7	25.3	12.6	1.0	5.9
Average							31.3	23.9	18.2	17.9	12.2	2.3	10.7
APAC ex- China peers													
KPJ	KPJ MK	NR	-	1.14	12	1,092	29.5	22.9	20.9	19.2	8.4	2.2	9.5
BDMS	BDMS TB	NR	-	26.75	12	11,477	33.9	31.4	29.1	26.9	18.5	2.0	14.8
BCH	BCH TB	NR	-	20.20	12	1,360	16.6	35.4	29.7	26.4	17.1	1.7	10.7
Bumrungrad Hosp	вн тв	NR	-	265.00	12	5,686	46.6	32.2	30.5	29.2	22.1	1.7	27.8
Chularat Hosp	CHG TB	NR	-	3.28	12	974	13.0	33.1	28.9	26.5	19.6	1.9	14.7
Fortis Healthcare	FORH IN	NR	-	339.65	03	3,025	49.8	41.8	33.6	27.1	20.0	0.1	7.8
Apollo Hosp	APHS IN	NR	-	5,118	03	8,690	89.8	68.2	47.2	35.3	29.5	0.2	15.0
PT Mitra Keluarga	MIKA IJ	NR	-	2,730	12	2,496	38.6	37.3	32.0	27.8	23.9	1.2	17.1
PT Siloam Int'l	SILO IJ	NR	-	2,100	12	1,753	39.1	27.7	24.0	20.6	10.7	0.9	12.7
Average							48.7	40.3	32.3	27.3	19.2	1.4	14.6
China peers													
China Resouces Med	1515 HK	NR	-	4.97	12	823	39.6	7.9	7.2	6.2	3.1	4.1	8.1
Aier Eye Hosp.	300015 CH	NR	-	17.97	12	22,950	66.7	48.6	37.2	28.9	27.5	0.6	16.4
Topchoice Med	600763 CH	NR	-	88.20	12	3,872	51.6	43.3	34.4	27.5	27.0	0.1	16.3
Average							63.8	46.6	35.9	28.1	26.7	0.6	16.1

Source: Bloomberg, FactSet, Maybank IBG Research

Fig 2: Forward 12-month P/E band



Source: FactSet

Fig 3: Forward 12-month P/B band



Source: FactSet

October 4, 2023 5



Fig 4: DCF valuation

Items (SGDm)	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
Revenue	739.7	749.5	763.1	778.6	796.1	815.8	837.6	861.9	888.7	918.2
Growth	-4%	1%	2%	2%	2%	2%	3%	3%	3%	3%
EBIT	164.3	170.9	178.5	182.0	186.4	191.7	197.8	204.8	212.6	221.3
Growth	-16%	4%	4%	2%	2%	3%	3%	4%	4 %	4%
Margin	22%	23%	23%	23%	23%	24%	24%	24%	24%	24%
add D&A	41.2	42.5	44.1	45.4	46.6	47.6	48.6	49.5	50.5	51.5
less tax paid & associates	(40.2)	(42.0)	(44.1)	(45.2)	(46.5)	(48.0)	(49.8)	(51.7)	(53.9)	(56.3)
less addition to WC	11.3	(0.5)	(0.7)	(0.8)	(0.9)	(1.1)	(1.2)	(1.4)	(1.6)	(1.9)
less capex	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)	(30.0)
FCFF	146.6	140.9	147.8	151.5	155.6	160.2	165.4	171.2	177.6	184.7
Terminal value										3922.2
PV	135.9	121.1	117.8	112.0	106.6	101.8	97.4	93.5	90.0	1928.9
Total discounted FCF	2905.1									
Less net debt	187.5									
No. of shares outstanding (m)	1,877.3									
TP	1.65									
Implied P/E	26.9									
implica i / L	20.7									

Source: Maybank IBG Research

Fig 5: DCF assumptions

Items		Comment
WACC (%)	8.0	RMG is net-cash over the long run
Cost of debt (%)	5.0	
Cost of equity (%)	8.0	
Beta (x)	0.8	Bloomberg: 0.7x. Reduced from 1x to factor in our view of lower China execution risks
Risk free rate (%)	2.5	-
Market return (%)	9.0	
LTG assumption (%)	3.0	

Source: Maybank IBG Research, Bloomberg

October 4, 2023 6

FYE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Key Metrics					
P/E (reported) (x)	27.2	16.4	19.2	18.4	17.5
Core P/E (x)	30.4	18.3	19.2	18.4	17.5
P/BV (x)	2.7	2.6	2.1	2.0	1.9
P/NTA (x)	2.7	2.6	2.1	2.0	1.9
Net dividend yield (%)	2.0	2.7	2.6	2.7	2.9
FCF yield (%)	3.8	5.5	6.2	6.0	6.3
EV/EBITDA (x)	15.5	10.4	10.4	9.7	8.9
EV/EBIT (x)	20.5	12.6	13.0	12.1	11.1
INCOME STATEMENT (SGD m)					
Revenue	723.8	766.5	739.7	749.5	763.1
EBITDA	160.6	236.1	205.5	213.4	222.6
Depreciation	(39.3)	(40.2)	(41.2)	(42.5)	(44.1)
Amortisation	0.0	0.0	0.0	0.0	0.0
EBIT	121.3	195.8	164.3	170.9	178.5
Net interest income /(exp)	(5.7)	(4.1)	(4.0)	(3.2)	(2.3)
Associates & JV	0.0	0.0	0.0	0.0	0.0
	0.0	0.0	0.0	0.0	0.0
Exceptionals Other protest income					
Other pretax income	0.0	0.0	0.0	0.0	0.0
Pretax profit	115.6	191.7	160.4	167.8	176.2
Income tax	(31.9)	(48.0)	(40.2)	(42.0)	(44.1)
Minorities	0.5	(0.2)	0.0	0.0	0.0
Discontinued operations	0.0	0.0	0.0	0.0	0.0
Reported net profit	84.2	143.5	120.2	125.7	132.1
Core net profit	84.2	143.5	120.2	125.7	132.1
BALANCE SHEET (SGD m)					
Cash & Short Term Investments	265.0	253.1	259.6	333.3	418.4
Accounts receivable	160.7	194.0	186.5	189.3	193.1
Inventory	13.4	13.1	13.4	13.6	13.8
Property, Plant & Equip (net)	797.4	739.1	810.0	805.5	793.4
Intangible assets	31.8	20.3	20.3	20.3	20.3
Investment in Associates & JVs	0.0	0.0	0.0	0.0	0.0
Other assets	277.0	278.1	278.1	278.1	278.1
Total assets	1,545.3	1,497.7	1,567.9	1,640.0	1,717.1
ST interest bearing debt	96.3	9.7	8.7	7.8	7.0
Accounts payable	253.6	223.8	227.9	230.3	233.6
LT interest bearing debt	77.9	63.4	63.4	63.4	63.4
Other liabilities		170.0	177.0	185.0	
Total Liabilities	141.0			486.6	194.0
	568.7	467.3	477.4		497.7
Shareholders Equity	960.8	1,015.1	1,075.2	1,138.0	1,204.1
Minority Interest	15.8	15.4	15.4	15.4	15.4
Total shareholder equity Total liabilities and equity	976.6 1,545.3	1,030.4 1,497.7	1,090.5 1,567.9	1,153.4 1,640.0	1,219.4 1,717.1
. ,	, ,	,	,	, ,	
CASH FLOW (SGD m)	115 4	101 7	160.4	147 0	174 2
Pretax profit	115.6	191.7		167.8	176.2
Depreciation & amortisation	39.3	40.2	41.2	42.5	44.1
Adj net interest (income)/exp	0.0	0.0	0.0	0.0	0.0
Change in working capital	14.2	(32.9)	11.3	(0.5)	(0.7)
Cash taxes paid	(21.7)	(29.1)	(40.2)	(42.0)	(44.1)
Other operating cash flow	0.0	0.0	0.0	0.0	0.0
Cash flow from operations	147.3	169.9	172.6	167.8	175.5
Capex	(49.9)	(24.9)	(30.0)	(30.0)	(30.0)
Free cash flow	97.4	145.1	142.6	137.8	145.5
Dividends paid	(37.3)	(52.0)	(60.1)	(62.9)	(66.0)
Equity raised / (purchased)	5.6	6.0	0.0	0.0	0.0
Change in Debt	3.2	(101.2)	(1.0)	(0.9)	(0.8)
change in bebt					
•	(20.6)	(34.5)	7.0	0.0	8.5
Other invest/financing cash flow Effect of exch rate changes	(20.6) 0.0	(34.5) 0.0	7.0 0.0	0.0 0.0	8.5 0.0

FYE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Key Ratios					
Growth ratios (%)					
Revenue growth	27.4	5.9	(3.5)	1.3	1.8
EBITDA growth	29.6	47.0	(12.9)	3.8	4.3
EBIT growth	37.2	61.4	(16.1)	4.0	4.5
Pretax growth	36.9	65.9	(16.3)	4.6	5.0
Reported net profit growth	27.7	70.5	(16.2)	4.6	5.0
Core net profit growth	27.7	70.5	(16.2)	4.6	5.0
Profitability ratios (%)					
EBITDA margin	22.2	30.8	27.8	28.5	29.2
EBIT margin	16.8	25.5	22.2	22.8	23.4
Pretax profit margin	16.0	25.0	21.7	22.4	23.1
Payout ratio	62.1	49.7	50.0	50.0	50.0
DuPont analysis					
Net profit margin (%)	11.6	18.7	16.3	16.8	17.3
Revenue/Assets (x)	0.5	0.5	0.5	0.5	0.4
Assets/Equity (x)	1.6	1.5	1.5	1.4	1.4
ROAE (%)	9.1	14.5	11.5	11.4	11.3
ROAA (%)	5.7	9.4	7.8	7.8	7.9
Liquidity & Efficiency					
Cash conversion cycle	(455.7)	(558.0)	(498.6)	(501.4)	(498.2)
Days receivable outstanding	68.2	83.3	92.6	90.3	90.2
Days inventory outstanding	35.1	37.7	36.8	37.0	36.9
Days payables outstanding	559.0	678.9	628.0	628.7	625.3
Dividend cover (x)	1.6	2.0	2.0	2.0	2.0
Current ratio (x)	1.1	1.4	1.4	1.6	1.9
Leverage & Expense Analysis					
Asset/Liability (x)	2.7	3.2	3.3	3.4	3.5
Net gearing (%) (incl perps)	net cash				
Net gearing (%) (met perps) Net gearing (%) (excl. perps)	net cash				
Net interest cover (x)	21.2	47.3	41.4	54.2	76.4
Debt/EBITDA (x)	1.1	0.3	0.4	0.3	0.3
Capex/revenue (%)	6.9	3.2	4.1	4.0	3.9
Superior Cremite (70)	0.7	3.2	(187.5)	1.0	3.7

Source: Company; Maybank IBG Research



Research Offices

ECONOMICS

Suhaimi ILIAS Chief Economist Malaysia | Philippines | Global (603) 2297 8682 suhaimi_ilias@maybank-ib.com

CHUA Hak Bin

Regional Thematic Macroeconomist chuahb@maybank.com

Dr Zamros DZULKAFLI Malaysia | Philippines (603) 2082 6818 zamros.d@maybank-ib.com

Erica TAY China | Thailand (65) 6231 5844 erica.tay@maybank.com

Brian LEE Shun Rong Indonesia | Singapore | Vietnam (65) 6231 5846 brian.lee1@maybank.

Fatin Nabila MOHD ZAINI (603) 2297 8685 fatinnabila.mohdzaini@maybank-ib.com

Luong Thu Huong (65) 6231 8467

hana.thuhuong@maybank.com

FX

Saktiandi SUPAAT Head of FX Research (65) 6320 1379 saktiandi@maybank.com

(65) 6320 1374 fionalim@maybank.com

Alan LAU (65) 6320 1378 alanlau@maybank.com

Shaun LIM (65) 6320 1371 shaunlim@maybank.com

STRATEGY

Anand PATHMAKANTHAN

ASEAN (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

FIXED INCOME

Winson PHOON, FCA Head of Fixed Income (65) 6340 1079 winsonphoon@maybank.com

(603) 2074 7606 munyi.st@maybank-ib.com

PORTFOLIO STRATEGY

ongsengyeow@maybank.com

MIBG SUSTAINABILITY RESEARCH

Jigar SHAH Head of Sustainability Research (91) 22 4223 2632 jigars@maybank.com

Neerav DALAL (91) 22 4223 2606 neerav@maybank.com

REGIONAL EQUITIES

Anand PATHMAKANTHAN Head of Regional Equity Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

WONG Chew Hann, CA Head of ASEAN Equity Research (603) 2297 8686 wchewh@maybank-ib.com

ΜΑΙ ΔΥSΙΔ

Anand PATHMAKANTHAN Head of Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com Strategy

WONG Chew Hann, CA (603) 2297 8686 wchewh@maybank-ib.com

Non-Bank Financials (stock exchange)
 Construction & Infrastructure

Desmond CH'NG, BFP, FCA (603) 2297 8680 desmond.chng@maybank-ib.com

Banking & Finance

ONG Chee Ting, CA (603) 2297 8678

ct.ong@maybank-ib.com
• Plantations - Regional

YIN Shao Yang, CPA (603) 2297 8916 samuel.y@maybank-ib.com

Gaming - Regional
 Media • Aviation • Non-Bank Financials

TAN Chi Wei, CFA (603) 2297 8690 chiwei.t@maybank-ib.com • Power • Telcos

WONG Wei Sum, CFA (603) 2297 8679 weisum@maybank-ib.com
• Property • Glove

Jade TAM (603) 2297 8687 jade.tam@maybank-ib.com
• Consumer Staples & Discretionary

Nur Farah SYIFAA (603) 2297 8675 nurfarahsyifaa.mohamadfuad@maybank-ib.com
• Renewable Energy • REITs

LOH Yan Jin (603) 2297 8687

lohyanjin.loh@maybank-ib.com
• Ports • Shipping • Automotive Arvind JAYARATNAM

(603) 2297 8692 arvind.jayaratnam@maybank.com · Petrochemicals · Technology

(603) 2297 8688 jeremie.yap@maybank-ib.com
• Oil & Gas Services

Jeremie YAP

TEE Sze Chiah Head of Retail Research (603) 2082 6858 szechiah t@maybank-ib com Retail Research

Nik Ihsan RAJA ABDULLAH, MSTA, CFTe (603) 2297 8694 kmohdihsan.ra@maybank-ib.com

• Chartist Amirah AZMI

(603) 2082 8769 amirah.azmi@maybank-ib.com · Retail Research

SINGAPORE

Thilan WICKRAMASINGHE Head of Research (65) 6231 5840 thilanw@maybank.com
Banking & Finance - Regional
Consumer

Eric ONG

(65) 6231 5849 ericong@maybank.com
• Healthcare • Transport • SMIDs

Kelvin TAN (65) 6231 5837 kelvin.tan1@maybank.com Telcos • Industrials

LI Jialin (65) 6231 5845 jialin.li@maybank.com REITs

Jarick SEET (65) 6231 5848 jarick.seet@maybank.com
• Technology

Krishna GUHA (65) 6231 5842 krishna.guha@maybank.com
REITs

PHILIPPINES

Jacqui de JESUS Head of Research (63) 2 8849 8840 jacqui.dejesus@maybank.com
• Strategy • Conglomerates

Rachelleen RODRIGUEZ, CFA (63) 2 8849 8843 rachelleen.rodriguez@maybank.com
• Banking & Finance • Transport • Telcos Utilities

Daphne SZE (63) 2 8849 8847 daphne.sze@maybank.com Consumer

Alexa Mae CARVAJAL (63) 2 8849 8838 alexamae.carvajal@maybank.com • Consumer • Gaming • Property • REITs

THAILAND

Chak REUNGSINPINYA Head of Research (66) 2658 5000 ext 1399 chak.reungsinpinya@maybank.com • Strategy • Energy

Jesada TECHAHUSDIN, CFA (66) 2658 5000 ext 1395 jesada.t@maybank.com • Banking & Finance

Wasu MATTANAPOTCHANART (66) 2658 5000 ext 1392 wasu.m@mavbank.com • Telcos • REITs

Surachai PRAMUALCHAROENKIT (66) 2658 5000 ext 1470 surachai.p@maybank.com
• Auto • Conmat • Contractor • Steel

Suttatip PEERASUB (66) 2658 5000 ext 1430 suttatip.p@maybank.com • Food & Beverage • Commerce

INDONESIA

Jeffrosenberg CHENLIM Head of Research (62) 21 8066 8680 jeffrosenberg.lim@maybank.com • Strategy • Banking & Finance • Property

Willy GOUTAMA (62) 21 8066 8500 willy.goutama@maybank.com • Consumer

Etta Rusdiana PUTRA (62) 21 8066 8683 etta.putra@maybank.com
• Telcos • Internet • Construction

William Jefferson W (62) 21 8066 8563 william.jefferson@maybank.com

 Property Adi WICAKSONO (62) 21 8066 8686 adi.wicaksono@mavbank.com

 Plantations Satriawan HARYONO, CEWA, CTA

(62) 21 8066 8682 satriawan@maybank.com Chartist

VIETNAM

Quan Trong Thanh Head of Research (84 28) 44 555 888 ext 8184 thanh.quan@maybank.com • Strategy • Banks

Hoang Huy, CFA (84 28) 44 555 888 ext 8181 hoanghuy@maybank.com • Strategy • Technology

Le Nguyen Nhat Chuyen (84 28) 44 555 888 ext 8082 chuyen.le@maybank.com
• Oil & Gas • Logistics

Nguyen Thi Sony Tra Mi (84 28) 44 555 888 ext 8084 trami.nguyen@maybank.com
Consumer Discretionary

Tran Thi Thanh Nhan (84 28) 44 555 888 ext 8088 nhan.tran@maybank.com Consumer Staples

Nguyen Le Tuan Loi (84 28) 44 555 888 ext 8182 loi.nguyen@maybank.com Property

Nguyen Thanh Hai (84 28) 44 555 888 ext 8081 thanhhai.nguyen@maybank.com
• Industrials

Nguven Thanh Lam (84 28) 44 555 888 ext 8086 thanhlam.nguyen@maybank.com • Retail Research



APPENDIX I: TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

DISCLAIMERS

This research report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. Investors should note that values of such securities, if any, may fluctuate and that each security's price or value may rise or fall. Opinions or recommendations contained herein are in form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from the relevant jurisdiction's stock exchange in the equity analysis. Accordingly, investors' returns may be less than the original sum invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Maybank Investment Bank Berhad, its subsidiary and affiliates (collectively, "Maybank IBG") and consequently no representation is made as to the accuracy or completeness of this report by Maybank IBG and it should not be relied upon as such. Accordingly, Maybank IBG and its officers, directors, associates, connected parties and/or employees (collectively, "Representatives") shall not be liable for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Any information, opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. Maybank IBG expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

Maybank IBG and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. One or more directors, officers and/or employees of Maybank IBG may be a director of the issuers of the securities mentioned in this report to the extent permitted by law.

This report is prepared for the use of Maybank IBG's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of Maybank IBG and Maybank IBG and its Representatives accepts no liability whatsoever for the actions of third parties in this respect.

This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. This report is for distribution only under such circumstances as may be permitted by applicable law. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

Malaysia

Opinions or recommendations contained herein are in the form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from Bursa Malaysia Securities Berhad in the equity analysis.

Singapore

This report has been produced as of the date hereof and the information herein may be subject to change. Maybank Research Pte. Ltd. ("MRPL") in Singapore has no obligation to update such information for any recipient. For distribution in Singapore, recipients of this report are to contact MRPL in Singapore in respect of any matters arising from, or in connection with, this report. If the recipient of this report is not an accredited investor, expert investor or institutional investor (as defined under Section 4A of the Singapore Securities and Futures Act), MRPL shall be legally liable for the contents of this report, with such liability being limited to the extent (if any) as permitted by law.

Thailand

Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Maybank Securities (Thailand) Public Company Limited. Maybank Securities (Thailand) Public Company Limited. Maybank Securities (Thailand) Public Company Limited ("MST") accepts no liability whatsoever for the actions of third parties in this respect.

Due to different characteristics, objectives and strategies of institutional and retail investors, the research products of MST Institutional and Retail Research departments may differ in either recommendation or target price, or both. MST reserves the rights to disseminate MST Retail Research reports to institutional investors who have requested to receive it. If you are an authorised recipient, you hereby tacitly acknowledge that the research reports from MST Retail Research are first produced in Thai and there is a time lag in the release of the translated English version.

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey may be changed after that date. MST does not confirm nor certify the accuracy of such survey result.

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, MST does not confirm, verify, or certify the accuracy and completeness of the assessment result.

US

This third-party research report is distributed in the United States ("US") to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Wedbush Securities Inc. ("Wedbush"), a broker-dealer registered in the US (registered under Section 15 of the Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Wedbush in the US shall be borne by Wedbush. This report is not directed at you if Wedbush is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Wedbush is permitted to provide research material concerning investments to you under relevant legislation and regulations. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security mentioned within must do so with: Wedbush Securities Inc. 1000 Wilshire Blvd, Los Angeles, California 90017, +1 (646) 604-4232 and not with the issuer of this report.

October 4, 2023 10



UK

This document is being distributed by Maybank Securities (London) Ltd ("MSUK") which is authorized and regulated, by the Financial Conduct Authority and is for Informational Purposes only. This document is not intended for distribution to anyone defined as a Retail Client under the Financial Services and Markets Act 2000 within the UK. Any inclusion of a third party link is for the recipients convenience only, and that the firm does not take any responsibility for its comments or accuracy, and that access to such links is at the individuals own risk. Nothing in this report should be considered as constituting legal, accounting or tax advice, and that for accurate guidance recipients should consult with their own independent tax advisers.

DISCLOSURES

Legal Entities Disclosures

Malaysia: This report is issued and distributed in Malaysia by Maybank Investment Bank Berhad (15938- H) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets and Services License issued by the Securities Commission in Malaysia. Singapore: This report is distributed in Singapore by MRPL (Co. Reg No 198700034E) which is regulated by the Monetary Authority of Singapore. Indonesia: PT Maybank Sekuritas Indonesia ("PTMSI") (Reg. No. KEP-251/PM/1992) is a member of the Indonesia Stock Exchange and is regulated by the Financial Services Authority (Indonesia). Thailand: MST (Reg. No.0107545000314) is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. Philippines: Maybank Securities Inc (Reg. No.01-2004-00019) is a member of the Philippines Stock Exchange and is regulated by the Securities and Exchange Commission. Vietnam: Maybank Securities Limited (License Number: 117/GP-UBCK) is licensed under the State Securities Commission of Vietnam. Hong Kong: MIB Securities (Hong Kong) Limited (Central Entity No AAD284) is regulated by the Securities and Futures Commission. India: MIB Securities India Private Limited ("MIBSI") is a participant of the National Stock Exchange of India Limited and the Bombay Stock Exchange and is regulated by Securities and Exchange Board of India ("SEBI") (Reg. No. INZ000010538). MIBSI is also registered with SEBI as Category 1 Merchant Banker (Reg. No. INM 000011708) and as Research Analyst (Reg No: INH000000057). UK: Maybank Securities (London) Ltd (Reg No 2377538) is authorized and regulated by the Financial Conduct Authority.

Disclosure of Interest

Malaysia: Maybank IBG and its Representatives may from time to time have positions or be materially interested in the securities referred to herein and may further act as market maker or may have assumed an underwriting commitment or deal with such securities and may also perform or seek to perform investment banking services, advisory and other services for or relating to those companies.

Singapore: As of 4 October 2023, Maybank Research Pte. Ltd. and the covering analyst do not have any interest in any companies recommended in this research report.

Thailand: MST may have a business relationship with or may possibly be an issuer of derivative warrants on the securities /companies mentioned in the research report. Therefore, Investors should exercise their own judgment before making any investment decisions. MST, its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the securities mentioned in this report.

Hong Kong: As of 4 October 2023, MIB Securities (Hong Kong) Limited and the authoring analyst do not have any interest in any companies recommended in this research report.

India: As of 4 October 2023, and at the end of the month immediately preceding the date of publication of the research report, MIBSI, authoring analyst or their associate / relative does not hold any financial interest or any actual or beneficial ownership in any shares or having any conflict of interest in the subject companies except as otherwise disclosed in the research report. In the past twelve months MIBSI and authoring analyst or their associate did not receive any compensation or other benefits from the subject companies or third party in connection with the research report on any account what so ever except as otherwise disclosed in the research report.

Maybank IBG may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment and may receive compensation for the services provided from the companies covered in this report.

OTHERS

Analyst Certification of Independence


The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

Reminder

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without the prior consent of Maybank IBG.

Historical recommendations and target price: Raffles Medical Group (RFMD SP)



Definition of Ratings

Maybank IBG Research uses the following rating system

BUY Return is expected to be above 10% in the next 12 months (including dividends)

HOLD Return is expected to be between 0% to 10% in the next 12 months (including dividends)

SELL Return is expected to be below 0% in the next 12 months (including dividends)

Applicability of Ratings

The respective analyst maintains a coverage universe of stocks, the list of which may be adjusted according to needs. Investment ratings are only applicable to the stocks which form part of the coverage universe. Reports on companies which are not part of the coverage do not carry investment ratings as we do not actively follow developments in these companies.



Malaysia

Maybank Investment Bank Berhad (A Participating Organisation of Bursa Malaysia Securities Berhad) 33rd Floor, Menara Maybank, 100 Jalan Tun Perak, 50050 Kuala Lumpur

Tel: (603) 2059 1888; Fax: (603) 2078 4194

Stockbroking Business: Level 8, Tower C, Dataran Maybank,

No.1, Jalan Maarof 59000 Kuala Lumpur Tel: (603) 2297 8888 Fax: (603) 2282 5136

Singapore

Maybank Securities Pte Ltd Maybank Research Pte Ltd 50 North Canal Road Singapore 059304

Tel: (65) 6336 9090

Indonesia

PT Maybank Sekuritas Indonesia Sentral Senayan III, 22nd Floor Jl. Asia Afrika No. 8 Gelora Bung Karno, Senayan Jakarta 10270, Indonesia

Tel: (62) 21 2557 1188 Fax: (62) 21 2557 1189

Thailand

Maybank Securities (Thailand) PCL 999/9 The Offices at Central World, 20th - 21st Floor, Rama 1 Road Pathumwan, Bangkok 10330, Thailand

Tel: (66) 2 658 6817 (sales) Tel: (66) 2 658 6801 (research)

Sales Trading

Indonesia Helen Widjaja helen.widjaja@maybank.com (62) 21 2557 1188

Philippines Keith Roy keith_roy@maybank.com Tel: (63) 2 848-5288

London

Greg Smith gsmith@maybank.com Tel: (44) 207-332-0221

India

Sanjay Makhija sanjaymakhija@maybank.com Tel: (91)-22-6623-2629

London

Maybank Securities (London) Ltd PNB House 77 Queen Victoria Street London EC4V 4AY, UK

Tel: (44) 20 7332 0221 Fax: (44) 20 7332 0302

India

MIB Securities India Pte Ltd 1101, 11th floor, A Wing, Kanakia Wall Street, Chakala, Andheri -Kurla Road, Andheri East, Mumbai City - 400 093, India

Tel: (91) 22 6623 2600 Fax: (91) 22 6623 2604

Vietnam

Maybank Securities Limited Floor 10, Pearl 5 Tower, 5 Le Quy Don Street, Vo Thi Sau Ward, District 3 Ho Chi Minh City, Vietnam

Tel: (84) 28 44 555 888 Fax: (84) 28 38 271 030

Hong Kong

MIB Securities (Hong Kong) Limited 28/F, Lee Garden Three, 1 Sunning Road, Causeway Bay, Hong Kong

Tel: (852) 2268 0800 Fax: (852) 2877 0104

Philippines

Maybank Securities Inc 17/F, Tower One & Exchange Plaza Ayala Triangle, Ayala Avenue Makati City, Philippines 1200

Tel: (63) 2 8849 8888 Fax: (63) 2 8848 5738

www.maybank.com/investment-banking www.maybank-keresearch.com